Finally, immunotherapy should be tested in SRCC, as PDL1 isoverexpressed in about 23% of cases of SRCC, and anti-PDL1/anti-PD1 antibodies are apromising treatment of gastric cancer.21 Overall, these results highlight that the classic FP combination orthe promising new targeted drugs are suboptimal in conferring a significant survivalbenefit in gastric SRCC patients in the perioperative or metastatic setting, andthat these patients could benefit from intensified and specific treatment. This evidence concerns the gene CD274 and gastric cancer.